Results 191 to 200 of about 1,082,657 (258)

Microbiota-gut-brain axis and bile acids-driven neuromodulation. [PDF]

Neural Regen Res
Dong T, Zhang T, Wang H, Zhang J, Abdullah R, Sun B, Peng G.   +6 more
europepmc   +1 more source

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

British Journal of Clinical Pharmacology, EarlyView.
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi, Masato Ozaka, Naoki Sasahira, Yasuhiko Sakata, Yuki Kogure, Shinya Tamaki, Atsushi Wada, Yusuke Taki, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Masakazu Yamaguchi, Kenichi Suzuki   +21 more
wiley   +1 more source

Bile acids and bile acid modification in health and disease: from novel modifications to therapeutic interventions. [PDF]

Front Endocrinol (Lausanne)
Yu C, Ye X, Zhao H, Qian S, Xie F, Liu Q.   +5 more
europepmc   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub, Armin Sepp, Amin Rostami‐Hodjegan, Brahim Achour   +3 more
wiley   +1 more source

Bile Acids: The Contribution of the Gut Microbiota to Atherosclerosis. [PDF]

Rev Cardiovasc Med
Xu L, Yang H, He C, Zhang H, Jiang Z, Zhang Y, Luan K, Hu H.   +7 more
europepmc   +1 more source

New therapeutic options for metabolic‐associated steatotic liver disease

British Journal of Clinical Pharmacology, EarlyView.
An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and ...
Tessa Straatmijer, Midas Mulder
wiley   +1 more source

Short-chain Fatty Acids and Bile Acids Signaling in Chronic Hepatitis B. [PDF]

J Clin Transl Hepatol
Sun S, Yang S, Yu Y, Chen J, Ning J, Yang Y, Jia H.   +6 more
europepmc   +1 more source

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu, Zeynep Betül Sarı, Muhammed Emin Sarı, Erdi Can Aytar   +3 more
wiley   +1 more source

Hepato-ocular crosstalk: Bile acids bridging pathogenesis and therapy. [PDF]

iScience
Wang P, Xie J, Xiang F, Xiong S, Li Y, Xia B, Lin L, Peng Q.   +7 more
europepmc   +1 more source

Echocardiography, Bile Acids and Spleen Stiffness to Rule Out High-Risk Varices in Children With Biliary Atresia. [PDF]

Liver Int
Lambert V, Teglas JP, Ackermann O, Franchi-Abella S, Tiret A, Veil R, Bernard O, Gonzales E, Jacquemin E, Duché M.   +9 more
europepmc   +1 more source